The VWD Minimize Study – Ages 18-45

Von Willebrand disease is an inherited bleeding disorder—caused by a missing or defective protein called von Willebrand factor—that prevents blood from clotting properly. Symptoms of von Willebrand disease can include excessive bleeding after injury or surgery, frequent nosebleeds, easy bruising, blood in the urine or stool, and bleeding from the gums. For women with von Willebrand disease, heavy menstrual flow is also a common problem that can lead to poor quality of life and anemia. Although treatments for the disorder exist, they are often ineffective or have significant side effects.

The purpose of this research study is to compare two different treatments, recombinant von Willebrand factor (rVWF) and tranexamic acid (Lysteda^®), for females with von Willebrand Disease who have heavy monthly periods. Both treatments are FDA-approved to treat heavy menstrual bleeding. Researchers hope their findings lead to better treatments for women and girls with von Willebrand disease in the future.

• Females aged 18-45
• Have Von Willebrand Disease
• Have heavy menstrual bleeding
• Have regular menstrual cycles (every 21-35 days)
• Not currently pregnant or breastfeeding
• Not using oral contraceptives (birth control pills) or contraceptive implants for the past 3 months [IUDs are permitted]
• Willing to undergo one baseline blood draw